Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Assessment of Molecular Breast Imaging (MBI) in Distinguishing Benign From Malignant Breast Disease

This study has been completed.
GE Healthcare
Information provided by (Responsible Party):
Christiane Hakim, University of Pittsburgh Identifier:
First received: September 11, 2012
Last updated: July 31, 2016
Last verified: July 2016
The primary hypothesis of this project is that using molecular breast imaging (MBI) in evaluating women with equivocal mammographic or sonographic findings will demonstrate high specificity in distinguishing benign from malignant breast disease and, as a result, decrease the number of biopsies.

Condition Intervention
Breast Abnormalities
Device: molecular breast imaging (Discovery)

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: The Assessment of Molecular Breast Imaging (MBI) in Distinguishing Benign From Malignant Breast Disease.

Resource links provided by NLM:

Further study details as provided by Christiane Hakim, University of Pittsburgh:

Primary Outcome Measures:
  • Specificity of MBI. Specificity is Defined as the Number of True Negatives/ Total Number of Negative Pathology Results. [ Time Frame: 1 year ]
    The number of indeterminate lesions with negative MBI uptake and negative/benign pathology results.Reported are number of indeterminate lesions with negative MBI uptake and negative/benign pathology results (true negatives).

Secondary Outcome Measures:
  • Sensitivity of MBI. Sensitivity in This Case is Defined as the Number of True Positives/ Total Number of Positive Pathology Results. [ Time Frame: 1 year ]
    Reported are the number of indeterminate lesions with marked, moderate, or mild uptake and positive pathology results (true positives).

Enrollment: 60
Study Start Date: September 2012
Study Completion Date: September 2014
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: molecular breast imaging Device: molecular breast imaging (Discovery)
Other Name: Discovery NM750b


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older
  • Women who have indeterminate mammographic or sonographic findings who are recommended and for biopsy

Exclusion Criteria:

  • Known contraindication to mammographic imaging
  • women who are pregnant
  • women who are lactating
  • women who have significant existing breast trauma
  • women who have breast implants
  • Women under 18 years of age.
  • women who had previous benign breast surgery within 1 year
  • Males and children
  • Women who are unable to understand or execute written informed consent
  • Women who refuse to have a biopsy
  • Women with any known renal disease - if an MRI is deemed necessary, a serum creatine will be checked prior to injection of contrast. Using the National Kidney Foundation recommendations, a glomerular filtration rate (GFR) greater than 60 may safely receive intravenous gadolinium-based MRI contrast. Those individuals with a GFR >30 and <60 can receive the contrast but at a reduced dose (typically half). Those with a GFR <30 will not receive MRI contrast and will not undergo the exam. Breast MRI must be done with contrast if evaluating for cancer. Several factors can affect the GFR such as age, body size, creatinine, renal status and will be calculated from the blood drawn. GFR is the final determinant and a creatinine greater than 1.6 usually has a GFR that precludes a Breast MRI with contrast. The final determinant will be the GFR.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01687790

United States, Pennsylvania
Hillman Cancer Center
Pittsburgh, Pennsylvania, United States, 15232
Sponsors and Collaborators
University of Pittsburgh
GE Healthcare
Principal Investigator: Christiane Hakim, MD University of Pittsburgh
  More Information

Responsible Party: Christiane Hakim, Principal Investigator, University of Pittsburgh Identifier: NCT01687790     History of Changes
Other Study ID Numbers: PRO12030005
Study First Received: September 11, 2012
Results First Received: January 27, 2016
Last Updated: July 31, 2016

Keywords provided by Christiane Hakim, University of Pittsburgh:
molecular breast imaging
breast disease
breast biopsy

Additional relevant MeSH terms:
Breast Diseases
Skin Diseases processed this record on May 25, 2017